Drug Discovery – AI.RadicalShift

interviewsVery Long Interview with Grok 3 on AI: The Great Handover: How AI is Reshaping Our World

Accelerated computing, Agent AI, AI assistants, AI models, Algorithms, Americas, Artificial Intelligence, Augmented reality, Automotive, Autonomous driving, Aviation & Aerospace, Chemicals, Datasets, Deep learning, Defence, Edge AI, Edge computing, Electronics & Machinery, Energy, Gas & Oil, Entertainment, Environment, Financial, Gaming, Generative AI, Graph neural network (GNN), Graphics Processing Unit (GPU), Healthcare, Internet & Online, LLMs (Large Language Models), Machine learning, Natural language processing (NLP), Neural networks, Pharma & Biotech, Quantum Computing, Science, Security & Safety, Semiconductors

March 14, 2025

Oleg Lazarov

2nm chips, Adobe’s AI, agentic AI, AGI, AI, AIVA’s tracks, Apple M-series, Apple’s Neural Engine, Apple’s Secure Enclave, AR, AutoGPT, automation, AWS SageMaker, biases, Black Box Blues, brain-computer interfaces (BCI), brain-signal-to-text, cancer patients, carbon-neutral cities, Cerebras, chain-of-thought, chain-of-thought reasoning, chiplets, CLIP, convolutional neural networks, creative collaboration, creativity, data synthesis, decision trees, decision-making, deep learning, Drug Discovery, Duolingo, edge AI, Edge chips, Education, energy efficiency, EU AI Act, Explainable AI, FedAvg, federated learning, generative adversarial networks (GANs), Georgia State’s AI system, GitHub, Google, Google’s DeepMind, Google’s VideoLLM, GPT-4, GPUs, Grok, Grok 3, Grok’s Toolkit, H200, hallucinations, Healthcare, high bandwidth memory (HBM3), HIPAA compliance, homomorphic encryption, human oversight, IBM, IBM Watson Health, IBM’s AI Fairness 360, innovation, Jasper, jobocalypse, Khan Academy, linear regression, LLMs, machine learning, March 14 2025, Meta, Meta’s SeamlessM4T, Microsoft’s Copilot, Midjourney, Mixture of Experts, modern AI, MS COCO, multimodal AI, natural language processing (NLP), Nest, neural networks, neuromorphic processors, No Man’s Sky, NVIDIA’s DLSS, NVIDIA’s Jetson, NVLink, OpenAI o1, OpenAI’s GPT-4o, Pepsi, personalized medicine, Pfizer, predictive models, privacy, PyTorch, Qualcomm Snapdragon, quantum computing, Rain Neuromorphics, reasoning algorithms, reasoning models, Reinforcement Learning from Human Feedback, remote work, RL, RLHF, robotics, RunwayML, Sakana AI, scientific discovery, self-driving cars, sepsis onset, SHAP, Siemens’ edge solutions, simulations, Slack, Smell data, softmax weights, support vector machines, sustainability, Sycamore, synthetic data, Tempus, TensorFlow, Tesla’s Full Self-Driving chips, TinyML, touch data, TPUs, traditional ML, transformers, TSMC, upskilling, ViT, VQA, VR, Wafer-Scale Engine, wearables, XAI

This interview with Grok, conducted between March 14 and 18, 2025, explored the multifaceted radical shifts AI is driving across the globe, reflecting RadicalShift.AI’s mission to obsessively observe these changes. We traversed a vast landscape—starting with AI’s implications for intellectual property, where it blurs ownership and challenges legal norms, to its ethical quandaries in military…
Continue Reading
analysesNVIDIA’s Role in Healthcare Innovation Feb 2025

Accelerated computing, Americas, Analytics, Artificial Intelligence, Big Data, Generative AI, Healthcare, Neural networks, Pharma & Biotech, Predictive analytics, Semiconductors

March 4, 2025

RadicalShift.AI

$10 trillion, 1993, 2025, AI, AlphaFold2, Amgen, Arc Institute, biologics, BioNeMo™, California, Clara, clinical trials, Cosmos Nemotron, CT, deCODE genetics, Deloitte, DGX Cloud, DGX SuperPOD, DGX systems, DiffDock 2.0, Drug Discovery, Freyja, genomics, GPUs, H100 Tensor Core GPUs, Healthcare, Iceland, Illumina, IQVIA, J.P. Morgan Healthcare Conference, Mayo Clinic, medical imaging, MONAI, MRI, NIM microservices, NVIDIA, Parabricks, precision medicine, ProteinMPNN, Quartz Atlas AI, RAPIDS, Reykjavik, RFdiffusion, Santa Clara, The Crick Team, TRACERx EVO, UC San Diego, ultrasound, Wellcome Sanger Institute

Key Points Nvidia is a tech leader in GPUs and AI, expanding into healthcare with innovative platforms. Partners with major healthcare firms like IQVIA, Illumina, Mayo Clinic, and Amgen for AI-driven solutions. Impacts drug discovery, medical imaging, genomics, and clinical trials, accelerating research and improving outcomes. Surprisingly, Nvidia’s AI helps predict protein properties for biologics,…
Continue Reading
newsQuantum Computing Inc. Partners with Sanders TDI to Advance Drug Discovery with Quantum Technology

Americas, Artificial Intelligence, Pharma & Biotech, Quantum Computing, Supercomputer

January 16, 2025

Sheryl Rivera

biomolecular modeling, cloud-based access, computational biomedicine, computational chemistry, Dirac-3 Entropy Quantum Computing Machine, Drug Discovery, Kettering Cancer Center, Memorial Sloan Weill Cornell Medicine, optimization problems, QCi, quantum analog computers, quantum computation, Quantum Computing Inc, quantum optics, quantum technologies, Sanders TDI, Sanders Tri-Institutional Therapeutics Discovery Institute, targeted therapeutics, The Rockefeller University

HOBOKEN, NJ — Quantum Computing Inc. (QCi), a leader in integrated photonics and quantum optics technology, has announced an exciting new collaboration with the Sanders Tri-Institutional Therapeutics Discovery Institute, Inc. (Sanders TDI) to advance research in computational biomedicine. This partnership will leverage QCi’s cutting-edge quantum computation technology, particularly its Dirac-3 Entropy Quantum Computing Machine, to…
Continue Reading
newsInfleqtion Demonstrates Groundbreaking Quantum Computing Experiment Using NVIDIA CUDA-Q Platform

AI assistants, AI models, Algorithms, Americas, Analytics, Artificial Intelligence, Automation, Industrial, Quantum Computing, Supercomputer

December 11, 2024

Oleg Lazarov

advanced quantum hardware, AI-powered supercomputers, breakthrough research, CUDA-Q™, Drug Discovery, environmental interactions, error correction, GPU-accelerated simulation, hardware imperfections, Infleqtion, logical qubits, logistics, materials science, noise, NVIDIA, quantum algorithms, quantum computing, quantum hardware, quantum supercomputing, quantum systems, scalable quantum systems, single-impurity Anderson model, Sqale neutral atom quantum processor, transformative applications

SANTA CLARA — Quantum computing is poised to revolutionize industries such as drug discovery and logistics, yet a significant obstacle remains: noise. Environmental interactions and hardware imperfections introduce disturbances that limit today’s quantum devices to just hundreds of operations before computations degrade. Addressing this challenge requires logical qubits, which combine tens or hundreds of physical…
Continue Reading
newsNVIDIA Unveils Open-Source BioNeMo Framework to Transform Drug Discovery and Biomolecular Research

AI assistants, AI models, Americas, Artificial Intelligence, Cloud, Datasets, Healthcare, Pharma & Biotech, Science, Semiconductors

November 19, 2024

Oleg Lazarov

AI research, AI tools, AlphaFold2, Argonne National Laboratory, biomolecular science, BioNeMo Blueprints, BioNeMo Framework, BioNeMo platform, biotechnology, cuEquivariance, DiffDock 2.0, digital biology, Drug Discovery, Dyno Therapeutics, Genentech, Ginkgo Bioworks, Kimberly Powell, molecular design, molecular modeling, NVIDIA, NVIDIA NIM™, open-source platform, pharmaceutical industry, ProteinMPNN, RFdiffusion, SC24, scalable AI deployments, supercomputing capabilities, virtual screening, Weights & Biases

SANTA CLARA — At SC24, NVIDIA announced the launch of its open-source BioNeMo Framework, a cutting-edge platform enabling global leaders in pharmaceuticals, biotechnology, and AI research to advance biomolecular science and accelerate drug discovery. Designed to address the challenges of scaling AI models in biomolecular research, BioNeMo brings supercomputing capabilities to biopharma, empowering researchers with…
Continue Reading
newsNVIDIA Powers Japan’s Healthcare Innovation with AI-Driven Advances in Drug Discovery, Genomics, and Medical Imaging

AI assistants, AI models, Americas, Artificial Intelligence, Asia, Data centers, Deep learning, Generative AI, Healthcare, LLMs (Large Language Models), Pharma & Biotech, Robotics, Supercomputer

November 12, 2024

Sheryl Rivera

aging population, AI, Astellas Pharma, CT imaging, Daiichi-Sankyo, DGX supercomputer, digital health, Drug Discovery, Fujifilm, genome sequencing, genomics, H100 Tensor Core GPUs, healthcare innovation, healthcare robotics, Holoscan, IOWN network, Japan, Jetson Orin modules, medical imaging, medical technology, Mitsui & Co, MONAI, NTT, NURA, NVIDIA, NVIDIA AI Summit Japan, NVIDIA BioNeMo, Olympus, Ono Pharmaceutical, Parabricks, precision medicine, Showa University, sovereign AI, surgical microscopy, Tokyo-1, University of Tokyo Human Genome Center, Xeureka

SANTA CLARA — Japan’s healthcare sector is embracing sovereign AI solutions to advance drug discovery, genomics, and medical device development, as healthcare providers and researchers innovate to meet the needs of an aging population. Nearly 30% of Japan’s citizens are over 65, and AI-driven healthcare is seen as vital to addressing an anticipated shortfall of…
Continue Reading
newsNVIDIA-Enabled AI and Confidential Computing Propel Mitsui’s Xeureka in Revolutionizing Drug Discovery

AI assistants, AI models, Americas, Artificial Intelligence, Asia, Generative AI, Healthcare, LLMs (Large Language Models), Pharma & Biotech, Supercomputer

November 12, 2024

Oleg Lazarov

AI, AI platform, AI supercomputer, autonomous trucking, chemical behaviors, confidential computing, data security, data sharing, digital transformation, Drug Discovery, Fortanix, geospatial analytics, global pharma, Healthcare, Hiroki Makiguchi, Japan, Katsuya Ito, large language models, ligand-base pairs, Mitsui & Co, molecular simulations, NVIDIA, NVIDIA BioNeMo, NVIDIA H100 Tensor Core GPUs, pharmaceutical industry, pharmaceutical R&D, predictive accuracy, protein structure prediction, quantum computing, Tokyo-1, Xeureka

SANTA CLARA — Mitsui & Co., a major Japanese conglomerate, is advancing drug discovery through its new subsidiary, Xeureka, which utilizes NVIDIA’s AI platform to securely harness shared datasets. Founded 77 years ago, Mitsui continues to innovate across its 16 divisions with digital transformation initiatives, ranging from autonomous trucking to geospatial analytics and even quantum…
Continue Reading
newsGoogle DeepMind’s Demis Hassabis and John Jumper Win Nobel Prize in Chemistry for AlphaFold Breakthrough

AI assistants, Analytics, Artificial Intelligence, Chemicals, Europe, Healthcare, Machine learning, Pharma & Biotech, Science

October 9, 2024

Sheryl Rivera

2024 Nobel Prize, AI, AlphaFold, AlphaFold Protein Structure Database, artificial intelligence, computational protein design, David Baker, DeepMind, Demis Hassabis, Drug Discovery, enzyme design, Google, Google DeepMind, groundbreaking discoveries, Isomorphic Labs, John Jumper, Nobel Prize in Chemistry, protein structure prediction, Royal Swedish Academy of Sciences, scientific research

LONDON — Demis Hassabis, Co-founder and CEO of Google DeepMind and Isomorphic Labs, and Dr. John Jumper, Director at Google DeepMind, have been jointly awarded the 2024 Nobel Prize in Chemistry for their pioneering work on AlphaFold, an AI system capable of accurately predicting the three-dimensional structure of proteins from their amino acid sequences. They…
Continue Reading
newsEmpowering Biopharma Innovation: Sartorius Expands Collaboration with NVIDIA for AI-driven Therapeutic Advancements

Algorithms, Americas, Analytics, Artificial Intelligence, Automation, Edge computing, Europe, Healthcare, Pharma & Biotech, Predictive analytics

May 16, 2024

Sheryl Rivera

3D-bioprinted spheroids, AI-powered computing platforms, biopharmaceutical, bioprocess design, bioprocessing, Clara suite, Drug Discovery, innovative therapies, laboratory instruments, life sciences, NVIDIA, organoids, precision medicine, predictive AI models, Prof. Dr. Oscar-Werner Reif, Sartorius, synthetic biological pathways, XETRA

GÖTTINGEN — Sartorius, a renowned life science group, is embarking on an expanded collaboration with NVIDIA, a leader in AI-powered computing platforms, to drive the development of new and improved therapies. This collaboration aims to merge Sartorius’ profound expertise in life sciences and bioprocessing with NVIDIA’s cutting-edge AI technologies to expedite biopharma drug discovery and…
Continue Reading
newsGoogle DeepMind Unveils AlphaFold 3 to Revolutionize Molecular Biology and Drug Discovery

AI assistants, Algorithms, Americas, Analytics, Artificial Intelligence, Europe, Healthcare, Machine learning, Pharma & Biotech

May 8, 2024

Sheryl Rivera

agriculture, AI model, AlphaFold 2, AlphaFold 3, AlphaFold Server, biological functions, biomolecular structures, cancer therapies, cell biology, DNA, Drug Discovery, environmental science, enzyme development, free access, genomics, Google DeepMind, health, Isomorphic Labs, ligands, molecular complexes, molecular interactions, pharmaceutical partners, precision medicine, proteins, RNA, sustainability, therapeutics, vaccine research

LONDON — Google DeepMind and Isomorphic Labs have unveiled AlphaFold 3, an innovative AI model that advances the understanding of molecular structures and interactions. Expanding on the success of AlphaFold 2, this new model predicts how proteins, DNA, RNA, ligands, and other biomolecules fit and interact, achieving up to a 50% accuracy increase in interaction…
Continue Reading
newsBenevolentAI Shifts Focus to AI-Driven Drug Discovery

Artificial Intelligence, Financial, Healthcare, Pharma & Biotech, Science

April 25, 2024

Oleg Lazarov

AI, AI-driven drug discovery, BenevolentAI, Dr. Joerg Moeller, Drug Discovery

LONDON — BenevolentAI (Euronext Amsterdam: BAI), a pioneering leader in AI-driven biopharma drug discovery, has outlined its updated business priorities, emphasizing a strategic shift towards maximizing returns for shareholders and advancing innovative medicines for patients. The company’s decision to concentrate on AI-driven drug discovery collaboration and its proprietary pipeline revenue-generating pillars comes after recent successes…
Continue Reading
newsNVIDIA Unveils New Healthcare Microservices for Advancing Medical Research and Patient Care

Americas, Analytics, Artificial Intelligence, Cloud, Generative AI, Healthcare

March 19, 2024

Oleg Lazarov

AI-driven healthcare, AI-powered agents, Amgen, BioNeMo™, Cadence, clinical conversation platforms, Drug Discovery, Flywheel, generative AI, genomics analysis, GTC conference, healthcare innovation, healthcare microservices, medical documentation, medical imaging, medical research, NVIDIA, NVIDIA AI Enterprise 5.0, NVIDIA NIM™, Orion®, patient care, public cloud platforms

SANTA CLARA — At the GTC conference today, NVIDIA introduced a suite of over two dozen microservices aimed at revolutionizing healthcare by harnessing the power of generative AI. These microservices, available on every NVIDIA DGX Cloud, offer optimized models and workflows for a range of applications, including drug discovery, medical imaging, and genomics analysis. By…
Continue Reading
newsNVIDIA Introduces New GPU-Accelerated Microservices for Enterprise AI Applications

Americas, Artificial Intelligence, Cloud, Cybersecurity, Generative AI, Healthcare, Industrial

March 18, 2024

Sheryl Rivera

Adobe, AI Enterprise 5.0, AI Models, certified systems, cloud platforms, Cloudera, CUDA platform, CUDA-X microservices, cybersecurity, data integration, Deepset, Dell Technologies, Drug Discovery, enterprise applications, generative AI microservices, GTC conference, high-performance computing, Jensen Huang, LlamaIndex, NeMo Retriever™ microservices, NIM microservices, NVIDIA, production deployment, SAP, ServiceNow

SANTA CLARA — At the GTC conference, NVIDIA unveiled a comprehensive catalog of enterprise-grade generative AI microservices designed to empower businesses to develop and deploy custom applications while retaining control over their intellectual property. Leveraging the NVIDIA CUDA® platform, these cloud-native microservices offer optimized inference capabilities across various domains, including language processing, drug discovery, and…
Continue Reading
newsMerck Partners with BenevolentAI and Exscientia for AI-Driven Drug Discovery

Artificial Intelligence, Europe, Healthcare, Pharma & Biotech

September 21, 2023

Sheryl Rivera

Artificial Intelligence (AI), BenevolentAI, Breakthrough Medicines, Danny Bar-Zohar, Data Science, Drug Discovery, Exscientia, Healthcare, immunology, innovation, Medical Innovation, Merck, Neurology, Oncology, Partnerships, R&D Processes, Research & Development, Small Molecule Development, Therapeutic Areas

DARMSTADT — Merck, a leading science and technology company, has unveiled two strategic drug discovery collaborations with BenevolentAI in London, U.K., and Exscientia in Oxford, U.K., signaling a significant advancement in its research endeavors. These partnerships are poised to leverage powerful artificial intelligence (AI)-driven design and discovery capabilities, aiming to generate a range of novel…
Continue Reading
newsBioNTech Strengthens AI Portfolio Through InstaDeep Acquisition

Artificial Intelligence, Europe, Healthcare, Investment, Machine learning, Pharma & Biotech

August 1, 2023

Oleg Lazarov

acquisition, AI, artificial intelligence, bioengineering, biomedical research, BioNTech SE, collaboration, Data Science, Drug Discovery, immunotherapies, InstaDeep Ltd., machine learning, ML, Software Development, vaccines

MAINZ — BioNTech SE (Nasdaq: BNTX) has finalized its acquisition of InstaDeep Ltd. (“InstaDeep”), a renowned global AI and machine learning technology company. The acquisition, initially announced on January 10, 2023, solidifies BioNTech’s commitment to advancing AI-driven drug discovery and developing cutting-edge immunotherapies and vaccines to tackle diseases with significant unmet medical needs. This move…
Continue Reading
newsNVIDIA Launches Cambridge-1: UK’s Premier Supercomputer Ignites AI Revolution in Healthcare and Research

Americas, Artificial Intelligence, Healthcare, Industrial, Pharma & Biotech, Quantum Computing, Semiconductors, Supercomputer

July 7, 2021

Sheryl Rivera

AI, AstraZeneca, Cambridge-1, digital biology, Drug Discovery, Frontier Economics, genomics, GSK, Guy’s and St Thomas’ NHS Foundation Trust, King’s College London, MRI scans, neurodegenerative diseases, NVIDIA, Oxford Nanopore, Oxford Nanopore Technologies, quantum computing, supercomputer, synthetic brain data

SANTA CLARA — NVIDIA has unveiled a landmark achievement in the realm of computational research with the official launch of Cambridge-1, the United Kingdom’s most potent supercomputer. Pioneering a new era of scientific exploration, Cambridge-1 promises to galvanize the efforts of top scientists and healthcare experts, leveraging the power of AI and simulation to propel…
Continue Reading
newsAI Revolutionizes Drug Discovery with Predictive Models for Effective Combinations

AI assistants, Algorithms, Americas, Analytics, Artificial Intelligence, Healthcare, Internet & Online, Machine learning, Pharma & Biotech

April 17, 2021

Oleg Lazarov

AI in medicine, AI-powered tools, biomedical research, cancer treatment, Compositional Perturbation Autoencoder, CPA, drug combinations, Drug Discovery, Facebook AI, gene expression, Helmholtz Zentrum München, machine learning, personalized medicine, pharmaceutical innovation, single-cell RNA sequencing

MENLO PARK — In a groundbreaking development, Facebook AI, in collaboration with Helmholtz Zentrum München, has introduced an innovative AI model designed to accelerate the discovery of effective drug combinations for complex diseases. This new model, known as the Compositional Perturbation Autoencoder (CPA), represents a significant advancement in the field of computational drug discovery, enabling…
Continue Reading
newsFacebook AI Unveils Breakthrough Model to Accelerate Discovery of Life-Saving Drug Combinations

Algorithms, Americas, Analytics, Artificial Intelligence, Europe, Healthcare, Open Source LLMs, Pharma & Biotech

April 16, 2021

Oleg Lazarov

academic researchers, AI-driven method, AI-powered tools, biological systems, biomedical research, cancer cells, cancer treatment, complex diseases, Compositional Perturbation Autoencoder, COVID-19, CPA model, drug combinations, Drug Discovery, drug interactions, drug optimization, drug repurposing, Facebook AI, gene alterations, gene expression, Helmholtz Zentrum München, in silico, machine learning, open-source tool, personalized medicine, pharmaceutical labs, pharmaceutical research, RNA sequencing, single-cell RNA sequencing

MENLO PARK — In a groundbreaking development, a new AI-driven method has been introduced to fast-track the discovery of effective drug combinations to combat complex diseases. Developed by Facebook AI in collaboration with Helmholtz Zentrum München, the Compositional Perturbation Autoencoder (CPA) model aims to predict the effects of drug combinations, dosages, and timing, while also…
Continue Reading
newsAstraZeneca and BenevolentAI Forge Groundbreaking AI Collaboration to Revolutionize Drug Discovery

Artificial Intelligence, Europe, Machine learning, Pharma & Biotech

April 30, 2019

Sheryl Rivera

AI, artificial intelligence, AstraZeneca, BenevolentAI, Chronic Kidney Disease, CKD, Drug Discovery, Idiopathic Pulmonary Fibrosis, IPF, Joanna Shields, machine learning, Mene Pangalos

CAMBRIDGE – AstraZeneca and BenevolentAI, leading innovators in healthcare and artificial intelligence (AI) respectively, have joined forces in a landmark partnership aimed at accelerating drug discovery processes, according to a press release published on EuropaWire. Harnessing the power of advanced AI and machine learning, the collaboration seeks to unlock new treatments for chronic kidney disease…
Continue Reading

What is RadicalShift AI?

RadicalShift.ai represents the paradigm shift the artificial intelligence (AI) brings upon all of us, from the way we live and work to the way we do business. To help cope with these fundamental changes across life, industries and the world in general, we are obsessively observing (30+ markets across multiple continents) and covering the AI industry while building a scalable open platform aimed at people, businesses and industry stakeholders to contribute across (benefit from) the entire spectrum of the AI industry from news, views, insights to knowledge, deployments, entities, people, products, tools, jobs, investors, pitch decks, and beyond, helping build what would potentially be a resourceful, insightful, knowledgeable and analytical source for AI related news, information and resources, ultimately becoming the AI industry graph/repository.

AI.RadicalShift

Tag: Drug Discovery

interviewsVery Long Interview with Grok 3 on AI: The Great Handover: How AI is Reshaping Our World

analysesNVIDIA’s Role in Healthcare Innovation Feb 2025

newsInfleqtion Demonstrates Groundbreaking Quantum Computing Experiment Using NVIDIA CUDA-Q Platform

newsNVIDIA Unveils Open-Source BioNeMo Framework to Transform Drug Discovery and Biomolecular Research

newsNVIDIA Powers Japan’s Healthcare Innovation with AI-Driven Advances in Drug Discovery, Genomics, and Medical Imaging

newsGoogle DeepMind’s Demis Hassabis and John Jumper Win Nobel Prize in Chemistry for AlphaFold Breakthrough

newsEmpowering Biopharma Innovation: Sartorius Expands Collaboration with NVIDIA for AI-driven Therapeutic Advancements

newsGoogle DeepMind Unveils AlphaFold 3 to Revolutionize Molecular Biology and Drug Discovery

newsBenevolentAI Shifts Focus to AI-Driven Drug Discovery

newsNVIDIA Unveils New Healthcare Microservices for Advancing Medical Research and Patient Care

newsMerck Partners with BenevolentAI and Exscientia for AI-Driven Drug Discovery

newsBioNTech Strengthens AI Portfolio Through InstaDeep Acquisition

newsNVIDIA Launches Cambridge-1: UK’s Premier Supercomputer Ignites AI Revolution in Healthcare and Research

newsAI Revolutionizes Drug Discovery with Predictive Models for Effective Combinations

newsFacebook AI Unveils Breakthrough Model to Accelerate Discovery of Life-Saving Drug Combinations

newsAstraZeneca and BenevolentAI Forge Groundbreaking AI Collaboration to Revolutionize Drug Discovery

What is RadicalShift AI?

Latest Entries

🏭 INDUSTRIES / MARKETS:

🏷️ TAGS

📂 ARCHIVE